Research Article

Bioinformatics Analysis Reveals MicroRNAs Regulating Biological Pathways in Exercise-Induced Cardiac Physiological Hypertrophy

Jiahong Xu,¹ Yang Liu,¹ Yuan Xie,¹ Cuimei Zhao,¹ and Hongbao Wang²

¹Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China
²Department of Cardiology, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, China

Correspondence should be addressed to Cuimei Zhao; zhaocuimei2000@126.com and Hongbao Wang; wanghongbao@tongji.edu.cn

Received 30 September 2016; Accepted 20 December 2016; Published 14 February 2017

Academic Editor: Diego Franco

Exercise-induced physiological cardiac hypertrophy is generally considered to be a type of adaptive change after exercise training and is beneficial for cardiovascular diseases. This study aims at investigating exercise-regulated microRNAs (miRNAs) and their potential biological pathways. Here, we collected 23 miRNAs from 8 published studies. MirPath v.3 from the DIANA tools website was used to execute the analysis, and TargetScan was used to predict the target genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses were performed to identify potential pathways and functional annotations associated with exercise-induced physiological cardiac hypertrophy. Various miRNA targets and molecular pathways, such as Fatty acid elongation, Arrhythmogenic right ventricular cardiomyopathy (ARVC), and ECM-receptor interaction, were identified. This study could prompt the understanding of the regulatory mechanisms underlying exercise-induced physiological cardiac hypertrophy.

1. Introduction

Cardiac hypertrophy, including physiological hypertrophy and pathological hypertrophy, is one of the most important adaptive mechanisms for the heart in various situations of stress [1]. Pathological cardiac hypertrophy is always associated with decreased cardiac dysfunction and poor prognosis, which can ultimately lead to heart failure [2]. In contrast, physiological hypertrophy induced by pregnancy or chronic exercise training is favourable for cardiac function [2]. Various epidemiological and experimental studies revealed that exercise training contributes to physiological cardiac hypertrophy, and it can attenuate the pathological hypertrophy related to cardiovascular diseases, such as myocardial infarction, heart failure, and cardiomyopathy [3, 4].

The biological mechanism underlying the physiological cardiac hypertrophy induced by exercise is complex and still incompletely elucidated [3]. In recent years, an increasing number of studies have identified that the microRNA (miRNA, miR) networks regulated by exercise could contribute to physiological cardiac hypertrophy [5]. miRNAs are a type of small noncoding RNA (18–23 bp) that can cause translational repression or cleavage of mRNAs and posttranscriptional silencing. miRNAs are considered to be promising therapeutic targets for numerous cardiovascular diseases and have been shown to play a key role in physiological hypertrophy by regulating various cellular functions, including decreasing fibrosis and apoptosis and inducing cell growth and angiogenesis [6]. Different studies focused on physiological hypertrophy identified various miRNAs and their potential pathways due to different experimental conditions; however, the most likely mechanism is still unclear [7–14]. In this study, we collected the current published data concerning miRNAs associated with physiological hypertrophy and predicted the most likely biological pathways underlying exercise-induced physiological cardiac hypertrophy using bioinformatics tools.
2. Methods

2.1. Data Extraction. We searched the PubMed website using the keywords “microRNA,” “exercise,” and “hypertrophy” to identify all of the published microRNAs associated with exercise-induced cardiac hypertrophy that were eligible for further bioinformatics analysis. We collected all the appropriate published articles and extracted all the data needed for further analysis.

2.2. Bioinformatics Analysis. The software MirPath v.3 from the DIANA tools website was used to identify potential miRNA target genes and pathways in our study. TargetScan was used in this study to predict the potential target genes and demonstrate the possible relationships among the databases. Pathway analysis was performed to determine the involvement of coexpressed genes in different biological pathways according to the Kyoto Encyclopedia of Genes and Genomes (KEGG). Gene Ontology (GO) analysis was used to investigate the pathways associated with biological processes, cellular components, and specific molecular functions corresponding to the target genes of miRNAs identified by the software TargetScan. In this study, $P$ values less than 0.05 ($P < 0.05$) were considered to be statistically significant.

3. Results

3.1. The Profiles of Identified miRNAs. As Table 1 shows, 8 studies were included in our study. Mouse models were used in 2 studies and rat models were used in another 6 studies to investigate the miRNAs regulated by various types of exercise [7–14]. Swimming, running, jumping, or wheel running were applied in the above studies. A total of 23 miRNAs were found to be associated with exercise-induced physiological cardiac hypertrophy. A total of 12 miRNAs were upregulated after exercise, while 14 miRNAs were downregulated, and 3 miRNAs showed different results in different reports.

3.2. KEGG and GO Pathway Analysis. KEGG pathway analysis was used to identify all the potential pathways corresponding to miRNAs regulated by exercise. As shown in Table 2 and Figure 1(a), the significant ($P < 0.05$) pathways corresponding to downregulated miRNAs were as follows: Fatty acid elongation, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Other types of O-glycan biosynthesis, Thyroid hormone synthesis, Tyrosine metabolism, Mucin type O-glycan biosynthesis, Other glycan degradation, Glycosphingolipid biosynthesis-lacto and neolacto series, Tryptophan metabolism, Gap junction, Proteoglycans in cancer,
Table 1: The microRNAs regulated by exercise.

| MicroRNAs                  | Exercise training         | Regulation | Reference       |
|----------------------------|----------------------------|------------|-----------------|
| MiR-133a (rno-miR-133a-3p) | Running & swimming         | Down       | 17468766 & 21447748 |
| MiR-1 (rno-miR-1-3p)       | Running & swimming         | Down       | 17468766 & 21447748 |
| MiR-27a (rno-miR-27a-3p)   | Swimming                   | Up         | 21709209        |
| MiR-27b (rno-miR-27b-3p)   | Swimming                   | Up         | 21709209        |
| MiR-143 (rno-miR-143-3p, mmu-miR-143-3p) | Swimming & wheel running | Down       | 21709209 & 24751578 |
| miR-26b (mmu-miR-26b-5p)   | Wheel running              | Down       | 24751578        |
| miR-150 (mmu-miR-150-3p)   | Wheel running              | Up         | 24751578        |
| miRNA-133b (rno-miR-133b-3p) | Swimming                  | Down       | 21447748        |
| miRNA-29c (rno-miR-29c-3p) | Swimming                   | Up         | 21447748        |
| miRNA-214 (rno-miR-214-3p) | Jumping                    | Down       | 25822872        |
| miR-208b (rno-mir-208b)    | Swimming                   | Up         | 25793527        |
| miR-30e (rno-miR-30e-5p)   | Swimming                   | Up         | 25793527        |
| miR-19b (rno-miR-19b-3p)   | Swimming                   | Up         | 25793527        |
| miR-99b (rno-miR-99b-5p)   | Swimming                   | Down       | 25793527        |
| miR-100 (rno-miR-100-5p)   | Swimming                   | Down       | 25793527        |
| miR-19a (rno-mir-19a)      | Swimming                   | Down       | 25793527        |
| miR-22 (rno-miR-22-3p)     | Swimming                   | Down       | 25793527        |
| miR-181a (rno-miR-181a-5p) | Swimming                   | Down       | 25793527        |
| miR-222 (mmu-miR-222-3p)   | Swimming & wheel running   | Up         | 25863248        |
| miRNA-21 (rno-miR-21-5p)   | Swimming                   | Up         | 23812090        |
| miRNA-145 (rno-miR-145-5p) | Swimming                   | Up         | 23812090        |
| miRNA-144 (rno-miR-144-3p) | Swimming                   | Up         | 23812090        |
| miRNA-124 (rno-miR-124-3p) | Swimming                   | Down       | 23812090        |

Table 2: The KEGG pathways incorporated by downregulated miRNAs.

| KEGG pathway                                                                 | $-\log(P$ value) | Genes                                                                 |
|-----------------------------------------------------------------------------|------------------|----------------------------------------------------------------------|
| Fatty acid elongation                                                       | 4.84             | Hadha, Elovl6                                                          |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC)                      | 2.94             | Cacng4, Cacna2dl, Sgcd, Jup, Igf8, Gja1                               |
| Other types of O-glycan biosynthesis                                        | 2.34             | B3glct, Pmt2, Fut9, Colgalnt2                                         |
| Thyroid hormone synthesis                                                  | 2.04             | Duox2, Tg                                                              |
| Tyrosine metabolism                                                        | 2.04             | Maa, Aldhl1a3                                                           |
| Mucin type O-Glycan biosynthesis                                           | 1.76             | Galnt16, Galnt7                                                        |
| Other glycan degradation                                                   | 1.66             | Neu3                                                                  |
| Glycosphingolipid biosynthesis-lacto and neolacto series                   | 1.66             | B3galnt2, Fut9                                                          |
| Tryptophan metabolism                                                      | 1.66             | Afmid, Hadha, Tph2, Maa, Ogdh1                                         |
| Gap junction                                                               | 1.66             | Tjpl, Egfr, Nras, Gm5, Gja1                                            |
| Proteoglycans in cancer                                                    | 1.66             | Wnt2, Ctn, Wnt4, Fgf1, Egfr, Fli1, Nras, Erbb3, Rock2, Flna, Fzd3, Wnt2b, Pik3cd, Cav3, Ppp1cc |
| Signaling pathways regulating pluripotency of stem cells                  | 1.57             | Fgf3, Wnt2, Wnt4, Fgf1, Nras, Nodal, Smad4, Fzd3, Wnt2b, Pik3cd, Acrv1c |

Gene Ontology (GO) analysis was used to investigate the pathways associated with biological processes, cellular components, and specific molecular functions corresponding to the target genes of microRNAs identified by the software TargetScan. The pathways corresponding to the target genes of downregulated microRNAs included cell, intracellular biological process, anatomical structure development, molecular function, cellular component, organelle, cell differentiation, embryo development, chromosome organization, anatomical and signalling pathways regulating pluripotency of stem cells. The significant pathways corresponding to upregulated microRNAs were as follows: ECM-receptor interaction, Fatty acid degradation, Fatty acid metabolism, Amoebiasis, Fatty acid elongation, Protein digestion and absorption, PI3 K-Akt signalling, Tyrosine metabolism, Other types of O-glycan biosynthesis, Glycosphingolipid biosynthesis-lacto and neolacto series, Valine, leucine and isoleucine degradation, and Focal adhesion (Table 3 and Figure 2(a)).
Table 3: The KEGG pathways incorporated by upregulated miRNAs.

| KEGG pathway                                    | −log(P value) | Genes                                                                 |
|-------------------------------------------------|--------------|----------------------------------------------------------------------|
| ECM-receptor interaction                        | 55.86        | Col2a1, Col3a1, Col6a3, Col1a1, Col4a4, Col5a2, Col5a3, Col4a3, Col1a1, Col4a2, Col5a1 |
| Fatty acid degradation                           | 16.12        | Hadha, Ehhadh, Acadm                                                  |
| Fatty acid metabolism                            | 9.93         | Hadha, Ehhadh, Acadm                                                  |
| Amoebiasis                                       | 6.21         | Col2a1, Col3a1, Col1a1, Prkx, Col4a4, Col5a2, Col5a3, Col4a1, Col4a3, Col1a1, Col4a2, Col5a1 |
| Fatty acid elongation                            | 4.85         | Hadha                                                                |
| Protein digestion and absorption                 | 3.93         | Col2a1, Col3a1, Col6a3, Col1a1, Col4a4, Col5a2, Col5a3, Col9a1, Col4a3, Col1a1, Atplb4, Col4a2, Col5a1 |
| PI3K-Akt signaling pathway                       | 2.81         | Tsc1, Col2a1, Col3a1, Ddit4, Fgf, Col6a3, Lpar6, Fgf12, Eif4b, Col1a1, Lrhl, Them4, Vegfa, Egrf, Ppp2ca, Ghr, Col4a, Tek, Col5a2, Osxr, Ppp2cb, Col5a, Ppp2rc, Gng5, Col4a, Col1a1, Myb, Gnb3, Col4a, Col5a, Kit |
| Tyrosine metabolism                              | 2.36         | Mboa, Idha3                                                          |
| Other types of O-glycan biosynthesis             | 2.23         | Pomp2, Fut9, Colga1t2                                                 |
| Glycosphingolipid biosynthesis-lacto and neolacto series | 1.81     | B3gal1t2, Fut9                                                       |
| Valine, leucine and isoleucine degradation       | 1.81         | Hadha, Ehhadh, Acadm                                                  |
| Focal adhesion                                   | 1.41         | Col2a1, Col3a1, Vav3, Col6a3, Col1a1, Vegfa, Crkl, Egrf, Col4a, Col5a2, Col5a3, Mylk, Col4a1, Col4a3, Col1a1, Col4a2, Col5a1, Ppp1csee interacti |

**Figure 2**: The KEGG and GO pathways incorporated by upregulated microRNAs.
structure formation involved in morphogenesis, ion binding, and cell morphogenesis (Figure 1(b)). Similarly, the following pathways corresponded to the upregulated miRNAs: cell, intracellular, anatomical structure development, biological process, cell differentiation, embryo development, ion binding, molecular function, proteinaceous extracellular matrix, organelle, basement membrane, anatomical structure formation involved in morphogenesis, collagen type IV trimer, extracellular matrix structural constituent, chromosome organization, and cell morphogenesis (Figure 2(b)).

4. Discussion

Exercise is widely known as a safe and well-accepted non-pharmacological strategy to improve cardiac function and protect the heart from cardiovascular disorders [15]. It is quite important to find the potential molecular pathways underlying the physiological cardiac hypertrophy induced by exercise. In recent years, an increasing number of studies have focused on miRNAs, which can inhibit the transcription of target miRNAs and regulate various biological pathways [16]. Various studies reveal that miRNAs regulated by exercise are associated with physiological cardiac hypertrophy processes [7, 8]. However, due to the various animal models and the various types of exercise training, different miRNAs and potential biological pathways have been reported in different studies. In several studies, some miRNAs were even reported to be regulated in opposite directions, and thus it is hard to determine which miRNAs and pathways are associated most with exercise-induced hypertrophy [8, 9]. In this study, we collected all the miRNA data from all the published articles about exercise-induced cardiac hypertrophy and investigated the most likely biological pathways using bioinformatics analysis.

The analysis of downregulated miRNAs regulated by exercise revealed that Fatty acid elongation pathway and Arrhythmogenic right ventricular cardiomyopathy (ARVC) pathway could be associated with the hypertrophy process. In the Fatty acid elongation pathway, ELOVL family member 6 (Elovl6) is a microsomal enzyme, which has been shown to regulate the monounsaturated fatty acids and elongation of C12–16 saturated fatty acids [17]. Elovl6 is associated with brown adipose tissue (BAT) thermogenic capacity, which could protect against cardiomyocyte injury and suppress cardiac remodelling in catecholamine-induced cardiomyopathy [18]. Our findings first indicate that exercise could contribute to physiological hypertrophy via regulating the Elovl6-BAT pathway. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is typically an autosomal dominant heart muscle disease, which is always accompanied by ventricular enlargement, heart dysfunction, and lethal arrhythmias [19]. ARVC is one of the most common primary reasons of sudden death in young people and athletes. Experimental and clinical studies indicated that exercise might induce ARVC [20]. In this study, we also elucidate the potential association between exercise and ARVC via miRNA regulation.

The analysis of upregulated miRNAs induced by exercise revealed that the ECM-receptor interaction pathway is the most valuable one. It was recently identified that in the mouse model of angiotensin II-induced cardiac remodelling, ECM-receptor interaction pathway may be involved in the process of cardiac remodelling [21, 22]. Here, we also indicate the relationship between this pathway and cardiac hypertrophy using bioinformatics analysis. This association needs to be more clearly elucidated in the future. We speculate that exercise can decrease fibrosis by targeting the ECM-receptor interaction pathway.

In conclusion, we predicted the most likely biological pathways associated with physiological cardiac hypertrophy induced by exercise in this study through extracting published miRNA data and performing analysis using bioinformatics methods, which may help us better understand the regulatory networks of exercise-induced physiological cardiac hypertrophy. However, more in-depth studies and clinical investigations are still needed in the future.

Competing Interests

The authors declare that there are no competing interests.

Authors’ Contributions

Jiahong Xu, Yang Liu, and Yuan Xie contributed equally to this work.

Acknowledgments

This study was supported by the grants from National Natural Science Foundation of China (81470515, 81673062, and 81270314 to Jiahong Xu, 81541007 to Hongbao Wang, and 81600228 to Cuimei Zhao), Natural Science Foundation of Shanghai (14ZR1438300 to Hongbao Wang), and Shanghai Medical Guide Project from Shanghai Science and Technology Committee (134119a3000 to Jiahong Xu).

References

[1] M. Samak, J. Fatullayev, A. Sabashnikov et al., “Cardiac hypertrophy: an introduction to molecular and cellular basis,” Medical Science Monitor Basic Research, vol. 22, pp. 75–79, 2016.

[2] I. Shimizu and T. Minamino, “Physiological and pathological cardiac hypertrophy,” Journal of Molecular and Cellular Cardiology, vol. 97, pp. 245–262, 2016.

[3] J. Roh, J. Rhee, V. Chaudhari, and A. Rosenzweig, “The role of exercise in cardiac aging: from physiology to molecular mechanisms,” Circulation Research, vol. 118, no. 2, pp. 279–295, 2016.

[4] S. Gielen, M. H. Laughlin, C. O’Connor, and D. J. Duncker, “Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations,” Progress in Cardiovascular Diseases, vol. 57, no. 4, pp. 347–355, 2015.

[5] T. Fernandes, V. G. Baraúna, C. E. Negrão, M. Ian Phillips, and E. M. Oliveira, “Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 309, no. 4, pp. H543–H552, 2015.
[6] J. Wang, O. W. Liew, A. M. Richards, and Y.-T. Chen, “Overview of microRNAs in cardiac hypertrophy, fibrosis, and apoptosis,” International Journal of Molecular Sciences, vol. 17, no. 5, article 749, 2016.

[7] A. Caré, D. Catalucci, F. Felicetti et al., “MicroRNA-133 controls cardiac hypertrophy,” Nature Medicine, vol. 13, no. 5, pp. 613–618, 2007.

[8] T. Fernandes, N. Y. Hashimoto, F. C. Magalhães et al., “Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin II, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7),” Hypertension, vol. 58, no. 2, pp. 182–189, 2011.

[9] N. C. Martinelli, C. R. Cohen, K. G. Santos et al., “An analysis of the global expression of microRNAs in an experimental model of physiological left ventricular hypertrophy,” PLOS ONE, vol. 9, no. 4, Article ID e93271, 2014.

[10] U. P. R. Soci, T. Fernandes, N. Y. Hashimoto et al., “MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats,” Physiological Genomics, vol. 43, no. 11, pp. 665–673, 2011.

[11] S. F. S. Melo, V. G. Barauna, M. A. Jr. Carneiro et al., “Resistance training regulates cardiac function through modulation of miRNA-214,” International Journal of Molecular Sciences, vol. 16, no. 4, pp. 6855–6867, 2015.

[12] S. Ramasamy, G. Velmurugan, K. S. Rajan, T. Ramprasath, and K. Kalpana, “MiRNAs with apoptosis regulating potential are differentially expressed in chronic exercise-induced physiologically hypertrophied hearts,” PLoS ONE, vol. 10, no. 3, Article ID e0121401, 2015.

[13] X. Liu, J. Xiao, H. Zhu et al., “MiR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling,” Cell Metabolism, vol. 21, no. 4, pp. 584–595, 2015.

[14] Z. Ma, J. Qi, S. Meng, B. Wen, and J. Zhang, “Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway,” European Journal of Applied Physiology, vol. 113, no. 10, pp. 2473–2486, 2013.

[15] T. M. H. Eijsvogels, K. P. George, and P. D. Thompson, “Cardiovascular benefits and risks across the physical activity continuum,” Current Opinion in Cardiology, vol. 31, no. 5, pp. 566–571, 2016.

[16] D. Lv, J. Liu, C. Zhao et al., “Targeting microRNAs in pathological hypertrophy and cardiac failure,” Mini-Reviews in Medicinal Chemistry, vol. 15, no. 6, pp. 475–478, 2015.

[17] T. Matsuzaka and H. Shimano, “Elovl6: a new player in fatty acid metabolism and insulin sensitivity,” Journal of Molecular Medicine, vol. 87, no. 4, pp. 379–384, 2009.

[18] C. Y. Tan, S. Virtue, G. Bidault et al., “Brown adipose tissue thermogenic capacity is regulated by Elovl6,” Cell Reports, vol. 13, no. 10, pp. 2039–2047, 2015.

[19] B. Pinamonti, F. Brun, L. Mestroni, and G. Sinagra, “Arrhythmic right ventricular cardiomyopathy: from genetics to diagnostic and therapeutic challenges,” World Journal of Cardiology, vol. 6, no. 12, pp. 1234–1244, 2014.

[20] F. M. Cruz, D. Sanz-Rosa, M. Roche-Molina et al., “Exercise triggers ARVC phenotype in mice expressing a disease-causing mutated version of human plakophilin-2,” Journal of the American College of Cardiology, vol. 65, no. 14, pp. 1438–1450, 2015.

[21] M.-Q. Dang, X.-C. Zhao, S. Dai et al., “Gene expression profile in the early stage of angiotensin ii-induced cardiac remodeling: a time series microarray study in a mouse model,” Cellular Physiology and Biochemistry, vol. 35, no. 2, pp. 467–476, 2015.

[22] L. Tao, Y. Bei, P. Chen et al., “Crucial role of miR-433 in regulating cardiac fibrosis,” Theranostics, vol. 6, no. 12, pp. 2068–2083, 2016.